Abstract Body

Global HIV surveillance estimates variably categorize adolescents (10-19 years) with children (<15 years), youth (15-24 years), and non-adults (<25 years).  At the end of 2013, there were 2.1 million adolescents living with HIV (ALHIV), 220,000 of whom had been newly infected that year.  In 2014, there were 3.9 million youth with HIV, of whom 2.8 million were in sub-Saharan Africa.  Almost two-thirds of all adolescents and youth with HIV are females.  Capturing adolescent data is particularly complex because these data represent a combination of perinatally and behaviorally infected ALHIV – a factor that is critical to understanding clinical and programmatic outcomes, but which is not disaggregated in surveillance or program evaluation.  These groups have substantially different social contexts and HIV disease experiences.  Perinatally infected ALHIV are frequently orphaned, highly treatment experienced, and experiencing long-term complications of their disease after a lifetime of immunosuppression.  Behaviorally infected ALHIV are coping with a relatively recent diagnosis, more often from key affected populations, have less severe disease and better immune function, and poorer treatment uptake.  Adherence and retention research has shown that older adolescents, who are more likely to be behaviorally infected, are twice as likely to be lost to follow-up compared to younger adolescents and older adults.  However, HIV-related mortality among ALHIV is more frequently due to deaths of the perinatally infected.  The persistent increase in ALHIV death compared to a 41% decrease observed in adults since 2005 represents a serious failure of the global HIV response.  When it was reported in 2014 that HIV was the second leading cause of death of adolescents worldwide and the most common cause of death in sub-Saharan Africa, policy makers and advocates began campaigning to promote investment into the continuum of prevention, testing, and care for adolescents.  In order to achieve current targets for reduction of new infections and expansion of care and treatment, resources would have to increase by at least 45%.  In addition, the quality of the strategic information used to monitor the ALHIV epidemic and the impact of programmatic interventions would need to improve by disaggregating surveillance data by age, sex, mode of exposure, and key population.